![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Xenazine, Xentra, Nitoman, others |
Other names | Ro-1-9569 |
AHFS/Drugs.com | Consumer Drug Information |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Low, extensive first pass effect |
Protein binding | 82–85% |
Metabolism | Liver (CYP2D6-mediated) |
Elimination half-life | 10 hours parent compound (2 to 8 hours active metabolites)[3] |
Excretion | Kidney (~75%) and fecal (7–16%)[4] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.348 |
Chemical and physical data | |
Formula | C19H27NO3 |
Molar mass | 317.429 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is sold under the brand names Nitoman and Xenazine among others. On August 15, 2008, the U.S. Food and Drug Administration approved the use of tetrabenazine to treat chorea associated with Huntington's disease. Although other drugs had been used "off label," tetrabenazine was the first approved treatment for Huntington's disease in the U.S.[5] The compound has been known since the 1950s.